139 related articles for article (PubMed ID: 15627066)
1. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
[TBL] [Abstract][Full Text] [Related]
4. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Ossolinska M
Oncol Res; 2006; 16(1):49-54. PubMed ID: 16783968
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
Han JY; Choi BG; Choi JY; Lee SY; Ju SY
Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
[TBL] [Abstract][Full Text] [Related]
9. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
Reeve JG; Morgan J; Schwander J; Bleehen NM
Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
[TBL] [Abstract][Full Text] [Related]
10. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
11. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
12. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer.
Oshita F; Ikehara M; Sekiyama A; Hamanaka N; Saito H; Yamada K; Noda K; Kameda Y; Miyagi Y
J Exp Ther Oncol; 2004 Jul; 4(2):155-60. PubMed ID: 15500010
[TBL] [Abstract][Full Text] [Related]
13. Serum endostatin levels in patients with lung carcinoma.
Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
[TBL] [Abstract][Full Text] [Related]
14. The cigarette burden (measured by the number of pack-years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients.
Duarte RL; Luiz RR; Paschoal ME
Lung Cancer; 2008 Aug; 61(2):244-54. PubMed ID: 18243408
[TBL] [Abstract][Full Text] [Related]
15. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
18. Serum pseudouridine as a biochemical marker in small cell lung cancer.
Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
[TBL] [Abstract][Full Text] [Related]
19. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
Biesma B; van de Werf PR; Melissant CF; Brok RG
Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
[TBL] [Abstract][Full Text] [Related]
20. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
